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Abstract
Background: There is evidence suggesting that actin binding to HIV-1 encoded proteins, or even
actin dynamics themselves, might play a key role in virus budding and/or release from the infected
cell. A crucial step in the reorganisation of the actin cytoskeleton is the engagement of various
different GTP binding proteins. We have thus studied the involvement of GTP-binding proteins in
the final steps of the HIV-1 viral replication cycle.
Results: Our results demonstrate that virus production is abolished when cellular GTP binding
proteins involved in actin polymerisation are inhibited with specific toxins.
Conclusion: We propose a new HIV budding working model whereby Gag interactions with pre-
existing endosomal cellular tracks as well as with a yet non identified element of the actin
polymerisation pathway are required in order to allow HIV-1 to be released from the infected cell.
Background
The final step in HIV-1 replication cycle is the release of
nascent viral particles from the infected cell. In this way,
HIV-1 acquires its lipid bilayer envelope by budding
through the plasma membrane of infected T CD4+ cells.
The only necessary and sufficient viral element for this
event to take place is the expression product of the gag
gene; i.e. the Pr55gag precursor [1]. Cells only expressing
Pr55gag are able to produce and release vesicles, called
viral-like particles (VLP), of size and morphology resem-
bling those of immature viral particles [2,3]. A discrete
functional sequence, referred to as the L domain encoded
by a PTAP motif in the C-terminal, p6 portion of the Gag
precursor, catalyses the pinching off of virus particles from
the plasma membrane. Indeed, as demonstrated by EM,
virus harbouring a modified L domain have been
observed to remain attached to the cell via a thin tether
[4]. Further work has shown that the interaction between
this viral domain and the cellular cytosolic Tsg101 (the
tumor susceptibility gene) molecule, that functions in the
biogenesis of the multivesicular body (MVB) endosomal
compartment [5], is critical for nascent virus detachment
from the plasma membrane of the infected T cell
[reviewed in 6].
The biological mechanism involved in the production of
either a vesicle or an enclosed membrane surrounded vir-
ion through membrane budding, implies plasma mem-
brane curvation prior to phospholipid bilayer fusion.
Plasma membrane dynamics are partially governed by
actin nucleation, a phenomenon in which several
cytosolic molecules, such as small GTP binding proteins
among others, are involved [7]. Interestingly, GTP bind-
ing protein-dependent actin nucleation, is also a key
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transport [reviewed in 8].
Previous studies reported that HIV-1 release from infected
cells could be blocked by disturbing the actin network
with specific toxins as Cytochalasin D (Cyto D) or
Mycalolyde B [9,10]. The published data shows that,
although structural viral proteins are transported and
localized to the inner face of the plasma membrane in
Cyto D treated cells, HIV-1 virions remain attached to the
cell, presenting the same phenotype as observed for L-
domain mutated viruses [9].
Since actin dynamics are involved in intracellular vesicu-
lar transport, and multiple actin nucleation events at the
cell cortex lead to the formation of a dense branched fila-
ment network that pushes the membrane forward [11],
we postulated that the actin polymerisation pathway itself
may play a crucial role in efficient HIV-1 release.
Results
Inhibition of small GTP-binding proteins abolishes HIV 
budding
We have tested the involvement of plasma membrane
related small GTP binding proteins in virus release, using
specific bacterial toxins. Toxin B from Clostridium difficile
inhibits Cdc42, Rho and Rac molecules by modifying the
protein structure through threonine glucosylation [12].
This modification blocks their ability to bind downstream
effectors, resulting in actin network disruption. We first
asked whether or not Toxin B treatment would interfere
with Gag budding and release in a system, where high lev-
els of HIV-1 Pr55gag, as the only viral protein, would be
produced. Expression of the HIV-1 Gag precursor, by
HeLa-CD4 cells, resulted in VLPs released to the media
(Fig. 1A and Material and Methods). The fact that VLP
related Pr55gag was neither degraded by Trypsin treat-
ment nor disassembled by Triton X-100 detergent addi-
tion, strongly suggested that the viral protein might be
surrounded by a lipid bilayer (Fig. 1A). Total degradation
of Pr55gag was only obtained after Trypsin treatment of
detergent solubilized material (Fig. 1A). Incubation of
HIV-1 Gag expressing HeLa-CD4 cells with increasing
amounts of Toxin B did not induce cell death, since more
than 95% of treated cells excluded the Trypan blue dye.
Interestingly, VLP release was inhibited in a dose depend-
ent manner with a maximum effect at a Toxin B concen-
tration of 4 ng/ml (Fig. 1A). Conversely, the overall
intracellular Gag production was not significantly modi-
fied in these experimental conditions, as shown by p24
quantification and western blot analysis of the soluble
fraction of detergent lysed treated cells (Fig. 1B, C). These
results show that Pr55gag release was abolished when
small GTP binding proteins such as Cdc42, Rac, and/or
Rho were inhibited.
Toxin B inhibits VLP releaseFigure 1
Toxin B inhibits VLP release. A. Toxin B dose dependent 
inhibition of VLP production. Supernatants of MVA infected/
HIV-1 Gag transfected HeLa-CD4 cells, treated or not with 
various concentrations of Toxin B for 16 h, were clarified by 
low speed centrifugation and treated or not (no) with 
Trypsin (ty), Triton X-100 (tx) or with Triton X-100 and 
Trypsin (tt). VLPs were recovered by centrifugation and sub-
jected to Western Blot analysis. B. Lysates of cells from panel 
A were subjected to Western Blot analysis. (mock: cells 
transfected with the vector without any insert, T+: is a cellu-
lar extract of HIV-1NDK infected H9 cells). C. p24 antigen was 
quantified in lysates from panel A by ELISA.Page 2 of 9
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cells, we tested the inhibition of virus production from
HIV-1NDK infected Jurkat cells in the presence of Toxin B,
exoenzyme C3 from Clostridium botulinum, and Lethal
Toxin 82 (LT) from Clostridium sordellii. Exoenzyme C3
ADP-ribosylates specifically Rho proteins, whereas LT glu-
cosylates specific Thr residues from Ras, Rap, Rac and Ral
proteins [12,13]. The human Jurkat T cell line was
infected with HIV-1NDK and maintained 4 days in culture.
After washing 3 times with PBS to ensure elimination of
previously produced viral particles, cells were grown for
another 20 h in complete medium (RPMI) in the presence
or absence of increasing amounts of toxins. The highest
toxin concentration used corresponds to the maximal
sub-lethal toxin concentration, defined as the maximal
toxin amount that did not kill the cell (observed by
Trypan blue exclusion) in our experimental system. Under
these conditions, toxin activity was confirmed by loss of
diffused cortical actin as well as actin aggregate formation,
monitored by immunofluorescence microscopy on Phal-
loidin-FITC treated cells. Cellular morphological changes
characterized by cell rounding and loss of numerous filo-
podial projections was also observed (Fig. 2). Gag and
actin co-localized both in treated and untreated cells (Fig.
2b–g). Whereas both proteins were exclusively seen in
membrane protrusions in infected untreated cells (Fig
2b), cortical actin disorganisation induced changes in
HIV-1 Gag distribution in toxin treated cells (Fig. 2c–g).
We further analysed the viral production capacity of HIV
infected T cells treated with the bacterial toxins. Cell cul-
ture supernatants of toxin treated or untreated cells were
harvested, and intracellular as well as extra cellular p24
antigen was quantified. The intracellular amount of p24
antigen was found to be identical for all cells; i.e. 27.1+/-
1.9 ng p24/105 cells. The release of p24 was unaffected by
C3 and LT but was drastically inhibited by Toxin B (Fig.
3A). These data strongly suggest that indeed active small
GTP binding proteins are necessary for HIV-1 to be
released from the infected target cell.
The increased amount of Toxin B required to inhibit VLP
formation in HeLa cells compared to that required to
abolish virus release in Jurkat cells (Fig. 1A and 3A) is due
to the susceptibility of each cell line to the action of the
toxin.
Unexpectedly, when infected Jurkat cells were incubated
in the presence of two different actin disrupting agents,
Cyto D or Iota Toxin, only Cyto D inhibited HIV produc-
tion (Fig. 3A), as already reported [9], whereas Iota toxin
did not. (fig 3A). Overnight incubation of HIV-1 infected
Jurkat cells with various concentrations of these toxins did
not induce cell death (as defined by Trypan blue exclu-
sion) and resulted in toxin-dependent actin
depolymerisation, as observed by immunofluorescence
microscopy on Phalloidin-FITC treated cells (Fig. 2f, g).
Since Cyto D reacts with elongating membrane interacting
actin [14], whereas Iota sequesters soluble actin mono-
mers [12], our result suggests that active nucleation at the
plasma membrane may be necessary for HIV production.
Inhibition of small GTP-binding proteins reduces infectivity 
of HIV-1 particles
We further investigated whether toxin treatments of HIV-
1 producing cells had any effect on the infectivity of the de
novo synthesized virions. Infectivity released into the cul-
ture media at the highest toxin concentration used in the
experiment represented in figure 3A, was quantified by
measuring the TCID50/p24 value of supernatants, as
described elsewhere [15] (Fig. 3B). Whereas Toxin B low-
ered the TCID50/p24 value of supernatants with a Toxin
treated/Toxin untreated TCID50/p24 ratio of about 0.1,
Cyto D only affected virus infectivity by a factor of 1.3
(Fig. 3B). This suggests that the infectivity of the small
amount of released virus from Cyto D treated cells
remained almost unchanged. Unexpectedly although C3,
Iota and LT did not alter p24 release from infected cells
(Fig. 3A), they reduced by about two-fold (Toxin treated/
Toxin untreated TCID50/p24 ratio ranging from 0.40 to
0.55) the infectivity of cell-free virus (Fig. 3B). This sug-
gests that the status of the actin network in virus-produc-
ing cells is relevant for the quality of the virus released into
the medium.
It is well documented that Gag assembly in the cytoplasm
of infected T cells is required as a key step prior to virus
budding [16]. Thus, the inhibition of virus production by
the action of toxins (Fig 3) could occur at the Gag assem-
bly level rather than at the level of an interaction between
plasma membrane actin polymerisation and the viral pro-
tein. In order to rule out this possibility, we studied the
assembly status of soluble cytoplasmic Pr55gag in toxin
treated cells by sucrose gradient analysis as already
reported [17]. HIV-1 infected Jurkat cells treated or not
with toxins were lysed in non denaturing conditions and
the resulting soluble fraction was loaded on a discontinu-
ous sucrose gradient (see Material and Methods section).
In all cases, Pr55gag was recovered in fractions 9–11, at a
relative density of about 1.15–1.20 g/ml (Fig. 4), corre-
sponding to assembled non-enveloped Gag structures
[18]. Thus, the observed toxin dependent inhibition of
virus production was indeed at the level of virus release,
and not a result of a modification of intracellular events
leading to Pr55gag assembling.
Discussion
In infected and transfected cells the HIV Gag precursor is
known to be targeted to the inner face of the plasma mem-
brane and to co-localise with actin. In our study we havePage 3 of 9
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Retrovirology 2005, 2:48 http://www.retrovirology.com/content/2/1/48Actin polymerisation and intracellular Gag distribution under toxin treatmentsFigure 2
Actin polymerisation and intracellular Gag distribution under toxin treatments. HIV-1 or mock infected Jurkat cells treated or 
not with 0.5 µg/ml toxins for 16 hours, were stained with Phalloidin-FITC (green) and p24 (red), in order to visualize actin 
organization and Gag distribution, respectively. A field of about 100 cells was studied for each condition, and the percentage of 
cells presenting disrupted (grey bar) or not (white bar) cortical actin pattern is represented as an histogram. "n": number of 
counted cells in the field. a) mock infected cells, b-g) HIV-1NDK infected cells. Untreated cells (a-b), cells treated with toxin B 
(c), LT (d), C3 (e), Cyto D (f), and Iota (g). Bar scale = 10 µm.Page 4 of 9
(page number not for citation purposes)
Retrovirology 2005, 2:48 http://www.retrovirology.com/content/2/1/48Engagement of small GTP binding proteins in HIV-1 releaseFi ur  3
Engagement of small GTP binding proteins in HIV-1 release. Jurkat HIV-1 infected cells were incubated for 20 h with various 
concentrations of bacterial toxins and Cyto D. A) Clarified supernatants of the culture medium were harvested for p24 quan-
tification by ELISA. Vertical axis indicates the relative HIV-1 production expressed as a percentage of the p24 antigen in the 
absence of toxin treatment. B) Titres of infectious virus (TCID50) released/pg of p24 from the highest toxin concentration dose 
from infected cells shown in panel A. Data presented corresponds to one out of three independent experiments. Each experi-
ment was performed in triplicate.Page 5 of 9
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in membrane protrusions (Fig. 2b), as previously shown
for SupT1 HIV-1 infected cells [19]. Interestingly,
incubation of HIV infected Jurkat cells with the toxins that
induced cortical actin disorganisation, produced changes
in HIV-1 Gag distribution (Fig. 2c–g). This result rein-
forces the previously reported physical interaction occur-
ring between the Gag precursor and actin [20-23], and
argues, as in Sasaki et al. [10], for a potential role for actin
dynamics in Pr55gag intracellular localisation.
We have found that disturbing cortical actin dynamics
inhibited virus production [Fig. 3A]. This was observed
either by modifying the polymerising actin itself, by Cyto
D action, or by inhibiting one key GTP binding protein
involved in a molecular pathway that leads to actin nucle-
ation, by Toxin B action. Some GTP binding proteins have
been shown to govern actin dynamics as well as intracel-
lular vesicular trafficking [8,24]. Since the viral Gag pre-
cursor does not travel through the secretory pathway [1] it
is reasonable to hypothesize that HIV virus budding and
actin polymerisation through activation of a GTP binding
protein may be linked. What is thus the molecular mech-
anism that can explain this observation? We found that
Toxin B abolished HIV-1 production whereas C3 and LT
did not. Knowing the spectrum of the toxins targets
[12,13], it can be inferred that Cdc42 might be a putative
cellular partner to virus release. Cdc42 has been found to
be specifically down-regulated in cells latently infected
with HIV, suggesting an important role for active Cdc42 in
virus infection [25]. It can thus be argued that active
Cdc42 may induce an actin polymerisation pathway and
allow virus budding and release. Analysis of virus produc-
tion from HIV infected cells harbouring inactive forms of
the Cdc42 molecule should help to ultimately define its
involvement in this event.
Our study concluded that C3, Iota and LT reduced infec-
tivity of virus produced. However these toxins did not
alter total virus production (Figure 3A and 3B). This sug-
gests that the capacity of the budding viral particle to
infect a new target cell is modified through disruption of
the actin web of the infected cell. How can actin be then
correlated to infection in this particular case? The most
possible explanation is based on the budding event itself.
HIV selectively incorporates cellular membrane proteins,
Toxin treatment does not affect intracellular HIV-1 Gag assemblyFigure 4
Toxin treatment does not affect intracellular HIV-1 Gag assembly. Non denaturing cytoplasmic lysates of HIV-1NDK Jurkat 
infected cells treated or not with 0.5 µg/ml of Toxin B, LT, or Cyto D for 16 h, were centrifuged through a discontinuous 
sucrose gradient. Eleven fractions were collected from top to bottom, concentrated by high speed centrifugation, and analysed 
by Western Blot. Vertical axis shows the sucrose density fractionation in g/ml. Arrows indicate Pr55gag migration.Page 6 of 9
(page number not for citation purposes)
Retrovirology 2005, 2:48 http://www.retrovirology.com/content/2/1/48that have been suggested to be involved in virus infectivity
[26], while budding from lipid raft domains at the plasma
membrane of the infected cell [27] where the Gag precur-
sor is mainly localised [28]. Since disruption of actin fila-
ments modifies the protein content of lipid rafts [29], the
action of the studied toxins on the infected cell might
modify the cellular protein content of the lipid raft. HIV
may then bud as a virus lacking a cellular component, or
harbouring an inhibitory cellular molecule.
Virus entry, by a membrane fusion mechanism, requires
actin nucleation [30] through activation of Rac-1 but not
Cdc42 or Rho proteins [31]. According to our results actin
network remodelling would be a key process for HIV rep-
lication, since it will play a crucial role in both early
(entry) and late (budding) infectious events, by involve-
ment of different sets of cellular GTP binding proteins.
Conclusion
We have shown that inhibiting small GTP binding pro-
teins involved in cortical actin dynamics disrupts virus
release. This is not the simple consequence of actin net-
work disorganisation since the action of LT, C3 and Iota
did not affect virus production. Our results suggest that
the actin polymerisation process, potentially via Cdc42 is
involved in the final step of the HIV replication cycle.
Analysis of recently published results shows that the
implication of intracellular protein transport pathways to
late endosomal compartments (i.e. the multivesicular
bodies compartment) acts as pre-existing cellular "tracks"
for the viral Gag protein-induced budding [32-34]. The
data presented here argues for a more complex working
model whereby in addition to using an intracellular
"track", HIV requires the specific exploitation of actin
dynamics in order to be released from the infected cell.
Further experimental studies should be done to define the
actin activation pathway used by Gag and the chronology
of the molecular events involved.
Materials and methods
Cell culture and transfection
C8166 and Jurkat cells were grown in RPMI 1640
medium, and HeLa-CD4 cells in MEM medium. Both
media were completed with 10% FCS, 2 mM glutamine
and 100 U/ml of penicillin-streptomycin.
Cells were infected with the Ankara strain/T7 RNA
polymerase (MVA) [35,36] at 1 pfu/cell, 30 min before
being transfected by fugene-6 (Roche, Basel, Switzerland)
with pos7 vector [36] or recombinant pos7-HIV-1Gag
[37].
VLP analysis
Supernatants of cells were harvested and clarified by low
speed centrifugation 24 h after transfection, and released
VLP were concentrated by centrifugation at 100,000 × g at
4°C through a 20% sucrose cushion. The resulted pellet
was resuspended in TNE and treated or not with 5 µg/ml
trypsine and /or 1% Triton X-100. Treated or mock-treated
VLPs were resolved on SDS 10% polyacrylamide gel and
transferred onto nitrocellulose membrane. Immunoblot-
ting was carried out with human polyclonal IgG purified
from HIV-1 positive individuals (HIVIg), followed by per-
oxydase-conjugated anti-human antibodies incubation.
HIV related proteins were detected using the ECL kit
(Amersham Biosciences, Upsala, Sweden).
Cell lysis and density gradient
Cytoplasmic lysates of 5*105 cells were fractionated
according to Gorvel et al. [38] with some modifications.
Briefly, cells were washed in PBS and resuspended in 0.5
ml of cold homogenisation buffer (HB) (250 mM sucrose,
3 mM imidazole, 0.1% gelatin) completed with the pro-
tease inhibitors cocktail (from Roche). Cell lyses was
obtained through 2 cycles of freezing and thawing. The
lysates were then clarified by centrifugation and the result-
ant post nuclear supernatants (PNS), were diluted to 1 ml
to obtain a final concentration of 32 % sucrose. A discon-
tinuous sucrose gradient was set up, from bottom to top,
as follows: 0.3 ml 62% sucrose, 0.3 ml 45% sucrose, 0.3
ml 35 % sucrose, 1 ml of diluted PNS, 0.6 ml 30%
sucrose, 0.6 ml 25% sucrose, 0.6 ml 20 % sucrose, and
centrifuged for 1 hr at 100,000 × g. Twelve fractions were
collected from top to bottom. An aliquot of each fraction
was used to determine the density by measuring the
refraction index with a refractometer. Each fraction was
diluted 1:3 in TNE buffer (10 mM Tris-HCl buffer pH 7,
0.1 M NaCl, 1 mM EDTA) and the assembled Gag protein
was recovered as a pellet, after concentration by high
speed centrifugation at 70,000 × g for 30 min. The pellets
were resuspended in Laemmli loading buffer, and submit-
ted to SDS 10% PAGE prior to Western Blot analysis.
Toxins
All toxins used in this study, but Cyto D, were purified as
in [39-41]. Cyto D was purchased from Sigma (France).
Cell infection
Jurkat cells were infected with HIV-1NDK at an MOI of 0.5
and maintained 4 days in culture at 5 × 105 cell/ml. After
3 washes in PBS the cells were grown for another 20 h in
complete medium containing serially diluted bacterial
toxins. Quantification of viral production by HIV-1 p24
ELISA (Organon Teknika, Boxtel, NL) was done on
supernatants, previously clarified by centrifugation at
1500 × g for 5 min. TCID50 was determined on C8166 T-
lymphocytes as previously described [20].Page 7 of 9
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Cells were incubated on polylysine-covered slides at room
temperature for 15 min and immediately fixed in
phosphate-buffered saline (PBS) (pH 7.4) containing
3.7% para-formaldehyde and 0.025% glutaraldehyde for
10 min. Fixed cells were treated 10 min in 0.1 M glycine
before being permeabilized in PBS containing 0.1% Sapo-
nine for 10 min. After two washes in PBS, cells were incu-
bated with 1% bovine serum albumin in PBS (pH 7.4) for
20–30 min. Immunofluorescence staining was performed
with phalloidin-FITC (Sigma Aldrich, France) and mono-
clonal anti p24 (Dako, France) followed by TRITC-labeled
anti-mouse antibody (Jakson). The specimens were ana-
lysed on a fluorescence microscope. Separate images were
taken in the corresponding channels, and merge images
were composed. Image acquisition and data processing
for all the samples were performed under the same
conditions.
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